CN114853854A - T cell epitope polypeptide LPYPDPSRIL derived from SARS-CoV-2 encoding protein and application thereof - Google Patents
T cell epitope polypeptide LPYPDPSRIL derived from SARS-CoV-2 encoding protein and application thereof Download PDFInfo
- Publication number
- CN114853854A CN114853854A CN202210423728.XA CN202210423728A CN114853854A CN 114853854 A CN114853854 A CN 114853854A CN 202210423728 A CN202210423728 A CN 202210423728A CN 114853854 A CN114853854 A CN 114853854A
- Authority
- CN
- China
- Prior art keywords
- cov
- sars
- cell
- cell epitope
- epitope polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 40
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 40
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 28
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 9
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 8
- 239000012642 immune effector Substances 0.000 claims description 6
- 229940121354 immunomodulator Drugs 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 108010067390 Viral Proteins Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 14
- 241000711573 Coronaviridae Species 0.000 abstract description 13
- 208000025721 COVID-19 Diseases 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract description 4
- 230000000295 complement effect Effects 0.000 abstract description 2
- 239000002773 nucleotide Substances 0.000 abstract description 2
- 125000003729 nucleotide group Chemical group 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 12
- 241000315672 SARS coronavirus Species 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 1
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 1
- YRZIYQGXTSBRLT-AVGNSLFASA-N Asp-Phe-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O YRZIYQGXTSBRLT-AVGNSLFASA-N 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- TWROVBNEHJSXDG-IHRRRGAJSA-N His-Leu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O TWROVBNEHJSXDG-IHRRRGAJSA-N 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- UCXQIIIFOOGYEM-ULQDDVLXSA-N Leu-Pro-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCXQIIIFOOGYEM-ULQDDVLXSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- LBSARGIQACMGDF-WBAXXEDZSA-N Phe-Ala-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 LBSARGIQACMGDF-WBAXXEDZSA-N 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- YFNOUBWUIIJQHF-LPEHRKFASA-N Pro-Asp-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O YFNOUBWUIIJQHF-LPEHRKFASA-N 0.000 description 1
- SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 description 1
- 101100499809 Rhodococcus erythropolis orf6-1 gene Proteins 0.000 description 1
- 108091007576 SARS-CoV-2 structural proteins Proteins 0.000 description 1
- KYKKKSWGEPFUMR-NAKRPEOUSA-N Ser-Arg-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KYKKKSWGEPFUMR-NAKRPEOUSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 description 1
- ADBFWLXCCKIXBQ-XIRDDKMYSA-N Trp-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ADBFWLXCCKIXBQ-XIRDDKMYSA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the technical field of biomedicine, in particular to T cell epitope polypeptide LPYPDPSRIL derived from a novel coronavirus (SARS-CoV-2) coding protein and application thereof. The amino acid sequence of the polypeptide is LPYPDPSRIL, which has the characteristics of inducing SARS-CoV-2 specific T cells and assisting in controlling SARS-CoV-2 infection and virus clearance. The invention also comprises fusion protein for coding the polypeptide epitope, a nucleic acid molecule of a nucleotide sequence or a complementary sequence thereof, a carrier containing the nucleic acid molecule, a pharmaceutical composition containing the polypeptide, the fusion protein, the nucleic acid molecule or the carrier as an active ingredient, and application of the polypeptide, the fusion protein, the nucleic acid molecule, the carrier and the pharmaceutical composition.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to T cell epitope polypeptide LPYPDPSRIL derived from a novel coronavirus (SARS-CoV-2) coding protein and application thereof.
Background
The novel coronavirus pneumonia caused by SARS-CoV-2 (COVID-19) is the public health problem which is most urgently solved at present in the world. COVID-19 has a great influence on the economic development of China and the world.
The specific T cell response targeting SARS-CoV-2 encoded virus protein (not limited to S protein) exists in COVID-19 patient, plays an important role in inhibiting SARS-CoV-2 infection and virus clearance, and may be helpful for patient recovery. Several recent studies have demonstrated that T lymphocyte numbers in patients with severe COVID-19 disease are significantly less in milder patients, suggesting that T cells play an important role in controlling or killing viruses. Meanwhile, clinical studies on patients with COVID-19 demonstrated that some patients were able to clear viral infections with persistent negative neutralizing antibodies targeting structural proteins in vivo. Several studies have shown that neutralizing antibodies targeting the SARS-CoV-2 structural protein exist in vivo for a short period of time. The significantly longer survival time of specific memory T cells in vivo has been compared, and this feature has been demonstrated in studies directed to MERS-CoV (middle east respiratory syndrome coronavirus) and SARS-CoV-1 (severe acute respiratory syndrome coronavirus), which are highly similar to SARS-CoV-2.
Furthermore, in a model using immunodeficient mice lacking T cells and B cells as hosts, researchers have found that reinfusion of mice infected with SARS-CoV-1(MA15 strain, mouse adapted 15strain) with virus-specific CD8+ T cells induced by a T cell epitope (S366) derived from SARS-CoV-1S protein accelerates viral clearance and clinical pathology recovery in mice. The epitope is used for immunizing BALB/C mice with a normal immune system, and after 7 days, the mice are infected with a lethal dose of SARS-CoV-1, and the immunized mice are found to accelerate the in vivo clearance of the virus and prevent 100 percent from the lethal effect of the virus; in contrast, the mortality rate of mice immunized with no or no-load dendritic cells was 70% and 50%, respectively. In another further animal experiment to investigate T cell epitopes as vaccines to provide sustained protection against SARS-CoV-1 infection, researchers immunized BALB/C mice with a T cell epitope derived from SARS-CoV-1S protein (S525), which was found to induce a vigorous T cell immune response and to detect the presence of virus-specific T cells in the lung and spleen. To investigate the protective effect of virus-specific memory T cells, mice were infected with a lethal dose of SARS-CoV-1 at days 42-45 after immunization, and mice immunized with epitope S525 were found to have 80% survival, compared to 0 and 20% survival for control mice immunized with no immunization and with GFP, respectively. Virus-specific memory CD8+ T cells were detected in recovered SARS-CoV-1 infection for 11 years, at which time neither neutralizing antibodies nor B cells producing neutralizing antibodies could be detected. Similarly, it was also found that mice immunized with a T cell epitope of MERS-CoV accelerated viral clearance and more rapidly recovered from the infected state using a mouse model infected with MERS-CoV. These findings indicate that the CoV (coronavirus) antigen-specific T cell-mediated cellular immune response plays an important role in controlling CoV infection and virus clearance.
When Antigen Presenting Cells (APC) or host cells infected by viruses express viral proteins, viral protein antigens in cytoplasm are degraded into peptide fragments by proteasomes, and the peptide fragments are transported and processed to be combined with Human Leukocyte Antigen (HLA) molecules to form Antigen peptide-HLA molecule complexes, and the Antigen peptide-HLA molecule complexes are transferred to the Cell surface to be recognized by T cells and activate the T cells. The key point of effectively exciting specific T cell immune response to exert antiviral effect lies in identifying T cell epitope from SARS-CoV-2 coding protein source, which is of great significance for developing safe and effective COVID-19 preventive and therapeutic polypeptide vaccine based on T cell epitope.
Disclosure of Invention
The invention aims to solve the technical problem of identifying T cell epitope from SARS-CoV-2 encoded protein to effectively stimulate specific T cell immune response to exert antiviral efficacy.
In order to solve the above problems, the present invention proposes the following technical solutions:
in a first aspect, the invention provides a T cell epitope polypeptide derived from SARS-CoV-2 encoded protein, the amino acid sequence of which is shown in any one of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6 and SEQ ID No. 7.
The invention also provides a nucleic acid molecule which comprises a nucleotide sequence for encoding the T cell epitope polypeptide derived from SARS-CoV-2 virus protein or a complementary sequence thereof.
The invention also provides vectors containing the nucleic acid molecules.
The invention also provides a fusion protein, which comprises the T cell epitope polypeptide derived from the SARS-CoV-2 virus coding protein.
The invention also provides an antigen presenting cell which is sensitized by the T cell epitope polypeptide derived from the SARS-CoV-2 virus coding protein.
Further, the antigen presenting cells are isolated and purified.
Further, the antigen presenting cell is selected from the group consisting of: dendritic cells, macrophages, B cells, fibroblasts, or endothelial cells.
The invention also provides a specific immune effector cell aiming at the T cell epitope polypeptide derived from the SARS-CoV-2 virus coding protein.
The invention provides a pharmaceutical composition containing T cell epitope polypeptide derived from SARS-CoV-2 virus encoding protein, which can contain nucleic acid molecule, vector, fusion protein, antigen presenting cell or specific immune effector cell as active components; the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient, which may be a vaccine in a pharmaceutically acceptable form.
The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, and refers to carriers of such agents: they do not themselves induce the production of antibodies harmful to the individual receiving the composition and are not unduly toxic after administration. Such vectors are well known to those of ordinary skill in the art. A thorough discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Sciences (Mack pub. co., n.j.1991). Such vectors include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, adjuvants, and combinations thereof.
Pharmaceutically acceptable carriers in pharmaceutical compositions may comprise liquids such as water, saline, glycerol and ethanol. In addition, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances and the like may also be present in these carriers. In addition, the immunological composition may further contain an immunological adjuvant.
Generally, the therapeutic compositions can be prepared as injectables, e.g., as liquid solutions or suspensions; solid forms suitable for constitution with a solution or suspension, or liquid carrier, before injection, may also be prepared.
Once formulated, the pharmaceutical compositions of the present invention can be administered directly to a subject. The subject to be prevented or treated may be an animal; especially a human.
The therapeutic or preventive pharmaceutical composition (including vaccine) containing the T cell epitope polypeptide derived from SARS-CoV-2 virus encoded protein can be applied by oral administration, subcutaneous administration, intradermal administration, intravenous injection and the like. The therapeutic dosage regimen may be a single dose regimen or a multiple dose regimen.
The invention provides application of T cell epitope polypeptide, nucleic acid molecule, vector, fusion protein, antigen presenting cell, specific immune effector cell or pharmaceutical composition derived from SARS-CoV-2 encoded protein in preparing medicine for treating or preventing SARS-CoV-2 virus infection.
The invention has the advantages that the T cell epitope polypeptide of SARS-CoV-2 coding protein source obtained by screening has the characteristics of inducing SARS-CoV-2 specific T cells and assisting in controlling SARS-CoV-2 infection and virus elimination. The in vitro experiment verifies that the epitope polypeptide has the capability of inducing SARS-CoV-2 specific T cells, and provides a theoretical basis for the subsequent development of polypeptide vaccines and diagnostic preparations based on SARS-CoV-2 protein source epitope.
Drawings
FIG. 1 is a statistical chart of ELISPOT spots obtained by inducing specific T cells in vitro by using T cell epitope polypeptide derived from SARS-CoV-2 encoded protein of the present invention, and detecting the number of specific T cells by using IFN-gamma targeted ELISPOT experiment.
FIG. 2 is a spot diagram of specific T cells induced by T cell epitope polypeptide derived from SARS-CoV-2 encoded protein in vitro and detected by using IFN-gamma targeted ELISPOT experiment.
Detailed Description
The present application will be further described with reference to the following examples, wherein unless otherwise indicated, the reagents, devices and materials are all commonly used or commercially available in the art, and the terms and abbreviations are used conventionally in the art, such as IL-2 (interleukin-2).
Experimental procedures without specific conditions noted in the following examples, generally followed by conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommendations.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
Examples
The invention provides epitope polypeptide derived from any one of SARS-CoV-2 coding protein:
m-1, M-3, ORF6-1, ORF6-3, ORF10-1, ORF10-2 and ORF1ab-3, and the amino acid sequences are shown as SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6 and SEQ ID No.7 in sequence.
And (3) verification experiment:
uses the epitope polypeptide to induce SARS-CoV-2 specific T cell which can be used for COVID-19 treatment in vitro.
(1) The PBMCs were resuspended in X-VIVO 15 medium (5% hAB added), added to 24-well plates to a concentration of 2-4M/well, and the epitope polypeptides described above were added individually to a final concentration of 10-20. mu.M.
(2) IL-2 was added to the final concentration of 25-50IU/mL 24 hours after polypeptide stimulation.
(3) After culturing for 8-10 days in a constant temperature incubator, collecting the PBMC stimulated by the polypeptide, washing for 2 times, and then resuspending to X-VIVO 15 culture medium for resting.
(4) After resting for 24-48 hours, specific T cells were detected using an enzyme-linked immunospot (ELISPOT) assay. The stimulated cells were divided into 4 ELISPOT plate wells (1-2X 10) coated with IFN-gamma (interferon-gamma) primary antibody 5 Each well of each cell), followed by incubation of 2 wells with epitope polypeptide and solvent control (DMSO) for 17-24 hours, respectively, followed by subsequent manipulations.
(5) The subsequent ELISPOT experiments were performed according to the instructions of the commercial kit (Mabtech, 3420-2H).
(6) And (5) reading the plate.
The results are shown in FIGS. 1 and 2.
Therefore, the T cell epitope polypeptide from SARS-CoV-2 encoded protein obtained by screening of the invention verifies that the epitope polypeptide has the capability of inducing SARS-CoV-2 specific T cells through in vitro experiments, and assists in controlling SARS-CoV-2 infection and virus clearance.
The T cell epitope polypeptide of SARS-CoV-2 coded protein source obtained by screening can provide theoretical basis for the subsequent development of polypeptide vaccine and diagnostic preparation based on SARS-CoV-2 protein source epitope.
While the invention has been described with reference to specific embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Sequence listing
<110> Shenzhen Shennuo transform medical institute; shenzhen jinuo immune Co Ltd
T cell epitope polypeptide derived from SARS-CoV-2 coding protein and application thereof
<130> 1
<141> 2022-04-21
<160> 7
<170> SIPOSequenceListing 1.0
<210> 1
<211> 9
<212> PRT
<213> Coronavirus
<400> 1
Phe Ala Tyr Ala Asn Arg Asn Arg Phe
1 5
<210> 2
<211> 9
<212> PRT
<213> Coronavirus
<400> 2
Lys Leu Leu Glu Gln Trp Asn Leu Val
1 5
<210> 3
<211> 9
<212> PRT
<213> Coronavirus
<400> 3
His Leu Val Asp Phe Gln Val Thr Ile
1 5
<210> 4
<211> 9
<212> PRT
<213> Coronavirus
<400> 4
Thr Phe Lys Val Ser Ile Trp Asn Leu
1 5
<210> 5
<211> 10
<212> PRT
<213> Coronavirus
<400> 5
Phe Ala Phe Pro Phe Thr Ile Tyr Ser Leu
1 5 10
<210> 6
<211> 9
<212> PRT
<213> Coronavirus
<400> 6
Asn Val Phe Ala Phe Pro Phe Thr Ile
1 5
<210> 7
<211> 10
<212> PRT
<213> Coronavirus
<400> 7
Leu Pro Tyr Pro Asp Pro Ser Arg Ile Leu
1 5 10
Claims (9)
1. A T cell epitope polypeptide derived from SARS-CoV-2 encoded protein, characterized in that its amino acid sequence is shown in SEQ ID No. 7.
2. A nucleic acid molecule encoding a T-cell epitope polypeptide derived from a SARS-CoV-2 viral protein according to claim 1.
3. A vector comprising the nucleic acid molecule of claim 2.
4. A fusion protein comprising a T cell epitope polypeptide derived from a SARS-CoV-2 virus-encoding protein according to claim 1.
5. An antigen presenting cell sensitized by a T-cell epitope polypeptide derived from a SARS-CoV-2 virus-encoding protein according to claim 1.
6. A specific immune effector cell against a T cell epitope polypeptide derived from SARS-CoV-2 virus encoded protein according to claim 1.
7. A pharmaceutical composition comprising as an active ingredient the polypeptide of claim 1, the nucleic acid molecule of claim 2, the vector of claim 3, the fusion protein of claim 4, the antigen presenting cell of claim 5 or the specific immune effector cell of claim 6.
8. The pharmaceutical composition of claim 7, further comprising a pharmaceutically acceptable carrier or excipient.
9. The polypeptide of claim 1, the nucleic acid molecule of claim 2, the vector of claim 3, the fusion protein of claim 4, the antigen presenting cell of claim 5, the specific immune effector cell of claim 6, or the pharmaceutical composition of claims 7-8 for use in the preparation of a medicament for treating or preventing a SARS-CoV-2 viral infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210423728.XA CN114853854A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide LPYPDPSRIL derived from SARS-CoV-2 encoding protein and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210423728.XA CN114853854A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide LPYPDPSRIL derived from SARS-CoV-2 encoding protein and application thereof |
| CN202110550991.0A CN113185586B (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide derived from SARS-CoV-2 coding protein and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110550991.0A Division CN113185586B (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide derived from SARS-CoV-2 coding protein and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114853854A true CN114853854A (en) | 2022-08-05 |
Family
ID=76982710
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210424166.0A Withdrawn CN114591401A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide HLVDFQVTI derived from SARS-CoV-2 encoding protein and application thereof |
| CN202210423728.XA Withdrawn CN114853854A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide LPYPDPSRIL derived from SARS-CoV-2 encoding protein and application thereof |
| CN202210424198.0A Withdrawn CN114560916A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide KLLEQWNLV derived from SARS-CoV-2 encoding protein and application thereof |
| CN202210424199.5A Withdrawn CN114560917A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide TFKVSIWNL derived from SARS-CoV-2 encoding protein and application thereof |
| CN202110550991.0A Active CN113185586B (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide derived from SARS-CoV-2 coding protein and application thereof |
| CN202210424226.9A Pending CN115925823A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide FAFPFTIYSL derived from SARS-CoV-2 encoding protein and application thereof |
| CN202210424250.2A Pending CN115925824A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide NVFAFPFTI derived from SARS-CoV-2 encoding protein and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210424166.0A Withdrawn CN114591401A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide HLVDFQVTI derived from SARS-CoV-2 encoding protein and application thereof |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210424198.0A Withdrawn CN114560916A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide KLLEQWNLV derived from SARS-CoV-2 encoding protein and application thereof |
| CN202210424199.5A Withdrawn CN114560917A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide TFKVSIWNL derived from SARS-CoV-2 encoding protein and application thereof |
| CN202110550991.0A Active CN113185586B (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide derived from SARS-CoV-2 coding protein and application thereof |
| CN202210424226.9A Pending CN115925823A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide FAFPFTIYSL derived from SARS-CoV-2 encoding protein and application thereof |
| CN202210424250.2A Pending CN115925824A (en) | 2021-05-18 | 2021-05-18 | T cell epitope polypeptide NVFAFPFTI derived from SARS-CoV-2 encoding protein and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (7) | CN114591401A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111217920A (en) * | 2020-03-10 | 2020-06-02 | 河北精硕生物科技有限公司 | N-S dominant epitope fusion protein of new coronavirus, preparation method and application thereof, expression protein, microorganism, application thereof and kit |
| CN111848753A (en) * | 2020-07-20 | 2020-10-30 | 中国科学院过程工程研究所 | Novel coronavirus epitope and application thereof |
| CN111939250A (en) * | 2020-08-17 | 2020-11-17 | 郑州大学 | Novel vaccine for preventing COVID-19 and preparation method thereof |
| RU2743593C1 (en) * | 2020-12-09 | 2021-02-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Peptide immunogens and vaccine composition against covid-19 with the use of peptide immunogens |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| CN114096675A (en) * | 2020-02-14 | 2022-02-25 | 艾天穆股份有限公司 | Coronavirus immunogenic compositions and uses thereof |
| CN111440229B (en) * | 2020-04-13 | 2021-08-03 | 中国人民解放军军事科学院军事医学研究院 | Novel coronavirus T cell epitope and application thereof |
| IL297335A (en) * | 2020-04-14 | 2022-12-01 | Univ California | Large sequence pan-coronavirus vaccine compositions |
| CN111548396B (en) * | 2020-04-17 | 2021-07-20 | 暨南大学 | Novel coronavirus T cell epitope peptide, pMHC, preparation and application thereof |
| CN111533812B (en) * | 2020-06-22 | 2020-10-27 | 艾立克(北京)生物科技有限公司 | DNA vaccine for SARS-COV-2 virus and its use |
| CN111944063A (en) * | 2020-08-20 | 2020-11-17 | 深圳市因诺转化医学研究院 | Fusion protein and nucleic acid molecule for specifically recognizing human CD19 chimeric antigen receptor and application thereof |
| CN116375822B (en) * | 2020-09-07 | 2024-06-25 | 重庆医科大学 | Novel coronavirus specific CD8+T cell epitope peptide and application thereof |
| CN112266411B (en) * | 2020-09-25 | 2022-06-24 | 北京诺思兰德生物技术股份有限公司 | Novel coronavirus vaccine and application thereof |
| CN111961138B (en) * | 2020-10-20 | 2021-03-30 | 苏州茂行生物科技有限公司 | Vaccine fusion proteins |
| CN112626090B (en) * | 2020-12-29 | 2021-08-10 | 艾棣维欣(苏州)生物制药有限公司 | Nucleotide sequence for coding novel coronavirus antigen and application thereof |
| CN112553172B (en) * | 2021-02-19 | 2021-08-03 | 苏州近岸蛋白质科技股份有限公司 | COVID-19 pseudovirus and preparation method and application thereof |
-
2021
- 2021-05-18 CN CN202210424166.0A patent/CN114591401A/en not_active Withdrawn
- 2021-05-18 CN CN202210423728.XA patent/CN114853854A/en not_active Withdrawn
- 2021-05-18 CN CN202210424198.0A patent/CN114560916A/en not_active Withdrawn
- 2021-05-18 CN CN202210424199.5A patent/CN114560917A/en not_active Withdrawn
- 2021-05-18 CN CN202110550991.0A patent/CN113185586B/en active Active
- 2021-05-18 CN CN202210424226.9A patent/CN115925823A/en active Pending
- 2021-05-18 CN CN202210424250.2A patent/CN115925824A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111217920A (en) * | 2020-03-10 | 2020-06-02 | 河北精硕生物科技有限公司 | N-S dominant epitope fusion protein of new coronavirus, preparation method and application thereof, expression protein, microorganism, application thereof and kit |
| CN111848753A (en) * | 2020-07-20 | 2020-10-30 | 中国科学院过程工程研究所 | Novel coronavirus epitope and application thereof |
| CN111939250A (en) * | 2020-08-17 | 2020-11-17 | 郑州大学 | Novel vaccine for preventing COVID-19 and preparation method thereof |
| RU2743593C1 (en) * | 2020-12-09 | 2021-02-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Peptide immunogens and vaccine composition against covid-19 with the use of peptide immunogens |
Non-Patent Citations (2)
| Title |
|---|
| TARKE ET AL.: "Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases", 《CELL REPORTS MEDICINE》, vol. 2, no. 100204, pages 1 * |
| YIPENG MA ET AL.: "Large-Scale Identification of T-Cell Epitopes Derived From Severe Acute Respiratory Syndrome Coronavirus 2 for the Development of Peptide Vaccines Against Coronavirus Disease 2019", 《THE JOURNAL OF INFECTIOUS DISEASES》, vol. 224, pages 956 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113185586A (en) | 2021-07-30 |
| CN115925823A (en) | 2023-04-07 |
| CN113185586B (en) | 2023-01-17 |
| CN114591401A (en) | 2022-06-07 |
| CN114560917A (en) | 2022-05-31 |
| CN114560916A (en) | 2022-05-31 |
| CN115925824A (en) | 2023-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3851120A1 (en) | Immunogen for broad-spectrum influenza vaccine and application thereof | |
| JP6811014B2 (en) | Vaccine against hepatitis B virus | |
| JP2021138721A (en) | Hiv pre-immunization and immunotherapy | |
| US20190106462A1 (en) | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection | |
| CN113666990B (en) | T cell vaccine immunogen for inducing broad-spectrum anti-coronavirus and application thereof | |
| EA016648B1 (en) | Use of replication–defective recombinant adenovirus comprising a heterologous nucleic acid encoding a cs antigen from a malaria-causing parasite and an adjuvated proteinaceous antigen comprising cs protein or a fragment thereof for the treatment or prevention of malaria | |
| US9630996B2 (en) | Attenuated recombinant vesicular stomatitis viruses comprising modified mutant matrix proteins | |
| EP2978449B1 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| US20230143215A1 (en) | Immunization against sars-cov-related diseases | |
| WO2023023940A1 (en) | Immunogen for inducing broad-spectrum anti-coronavirus t cell vaccine and use thereof | |
| EP3013960A1 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| Shi et al. | The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization | |
| WO2023160654A1 (en) | Preparation and use of recombinant multicomponent sars-cov-2 trimeric protein vaccine capable of inducing broad-spectrum neutralizing activity | |
| JPH07504662A (en) | Immune stimulants for therapeutic use in immunocompromised hosts | |
| CN113185586B (en) | T cell epitope polypeptide derived from SARS-CoV-2 coding protein and application thereof | |
| Hsieh et al. | The effect of co-administration of DNA carrying chicken interferon-γ gene on protection of chickens against infectious bursal disease by DNA-mediated vaccination | |
| WO2022105880A1 (en) | Fusion gene, recombinant novel coronavirus high-efficiency immune dna vaccine, construction method therefor and use thereof | |
| JP2010029217A (en) | Hiv-specific ctl inducing peptide and medicament for preventing or treating aids comprising the peptide | |
| Jiang et al. | Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model | |
| US8465748B2 (en) | Vaccine compositions and methods containing an immunogen derived from equine arteritis virus | |
| KR102211077B1 (en) | A pseudo type rabies virus vaccine using virus-like particles | |
| CN110382518B (en) | Chimeric vaccine for serotype A foot and mouth disease virus | |
| CN112426523A (en) | Pig vaccine containing antiviral composition and application | |
| Ye et al. | Immunization with a mixture of HIV Env DNA and VLP vaccines augments induction of CD8 T cell responses | |
| CN114272364B (en) | Mycobacterium tuberculosis tandem DNA vaccine W541 and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220805 |